Gedatolisib, when combined with Faslodex (fulvestrant) and Ibrance (palbociclib), has demonstrated significant improvements in progression-free survival for patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. This innovative triple combination therapy has shown to be well-tolerated and resulted in a substantial increase in median progression-free survival compared to standard treatments.
The results from the VIKTORIA-1 trial have the potential to revolutionize the treatment landscape for patients with advanced breast cancer, offering new hope and better outcomes for those who have progressed on previous therapies. Dr. Igor Gorbatchevsky, chief medical officer of Celcuity, expressed enthusiasm about the transformative potential of gedatolisib and the paradigm-shifting results observed in the trial. This breakthrough therapy targets the PI3K/AKT/mTOR pathway and represents a significant advancement in precision medicine for breast cancer treatment.
Read more from curetoday.com